Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Net Income (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Net Income data on record, last reported at -$5.9 million in Q3 2025.

  • For Q3 2025, Net Income rose 16.59% year-over-year to -$5.9 million; the TTM value through Sep 2025 reached -$24.1 million, up 14.5%, while the annual FY2024 figure was -$26.1 million, 7.68% up from the prior year.
  • Net Income reached -$5.9 million in Q3 2025 per MBRX's latest filing, down from -$5.7 million in the prior quarter.
  • Across five years, Net Income topped out at -$5.2 million in Q4 2021 and bottomed at -$9.0 million in Q3 2022.
  • Average Net Income over 5 years is -$6.6 million, with a median of -$6.2 million recorded in 2021.
  • Peak YoY movement for Net Income: tumbled 81.35% in 2021, then soared 37.86% in 2023.
  • A 5-year view of Net Income shows it stood at -$5.2 million in 2021, then crashed by 32.96% to -$6.9 million in 2022, then dropped by 25.07% to -$8.7 million in 2023, then rose by 23.81% to -$6.6 million in 2024, then grew by 11.07% to -$5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$5.9 million in Q3 2025, -$5.7 million in Q2 2025, and -$5.9 million in Q1 2025.